Subscribe

Sensorion S.A. (ALSEN.PA)

EUR0.27 +0.01 (+3.85%)
FR PAR Healthcare Biotechnology
Address 375, rue du Professeur Joseph Blayac 34080
Montpellier, FR
CEO Amit D. Munshi
Website sensorion.com
IPO 2015-04-21
ISIN FR0012596468

Explore sections of this company profile

Also trades on Euronext Paris · ALSEN.PA (EUR) Other OTC · SENOF (USD)
Description

Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR0.27 +0.01 (+3.85%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.38
Float Shares
265.11M
Free Float %
86.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.04% +2.82% -0.74% +10.47% +24.53% +18.99% -0.25% +44.77% -80.34% -92.99% -91.17%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.27
DCF (Unlevered) 0.09 -68.4%
DCF (Levered) 0.06 -76.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 80% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 4 0
Hold 1 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1.27
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -100.0% Q4'25: -100.0% (vs Q4'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    -7.0% Q4'25: +14.7% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    —
  • ✗
    EBIT margin Biotechnology: +0.0%
    —
  • ✓
    ROIC Biotechnology: -16.1%
    — Q4'25: +3,822.8% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +5.9% Q4'25: +60.9% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.04× Q4'25: -0.02× (vs Q4'23)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.36) × ERP
WACC = 99% × Ke + 1% × Kd (21.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.09 Current price: 0.27
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
5 Rev. Ana.
4 EPS Ana. 		Dec 2027
2 Rev. Ana.
2 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
17.5K
est: 1.50M (-98.8%)
1.93M
est: 1.54M (+25.5%)
2.46M
est: 2.60M (-5.5%)
2.35M
est: 3.27M (-28.0%)
4.26M
est: 4.37M (-2.4%)
4.93M
est: 2.50M (+97.3%)
5.70M
est: 6.15M (-7.3%)
6.65M
est: 13.01M (-48.9%)
—
est: 5.31M (-100.0%)
18.88M
17.15M – 20.61M
+255.9% YoY
4.82M
4.38M – 5.26M
-74.5% YoY
7.04M
6.40M – 7.69M
+46.1% YoY
132.68M
120.55M – 144.82M
+1,783.6% YoY
191.54M
174.02M – 209.06M
+44.4% YoY
EBITDA
-8.72M
est: -1.50M (-481.2%)
-9.29M
est: -1.54M (-502.9%)
-10.67M
est: -2.60M (-310.5%)
-10.26M
est: -3.27M (-214.0%)
-17.46M
est: -4.37M (-299.5%)
-22.44M
est: -2.50M (-797.7%)
-21.33M
est: -3.69M (-478.3%)
-27.58M
est: -7.81M (-253.3%)
-35.21M
est: -3.18M (-1,006.1%)
-11.33M
-12.37M – -10.29M
-255.9% YoY
-2.89M
-3.16M – -2.63M
+74.5% YoY
-4.23M
-4.61M – -3.84M
-46.1% YoY
-79.61M
-86.89M – -72.33M
-1,783.6% YoY
-114.92M
-125.44M – -104.41M
-44.4% YoY
EBIT
-9.07M
est: -1.50M (-504.6%)
-9.61M
est: -1.54M (-523.5%)
-10.78M
est: -2.60M (-314.4%)
-10.67M
est: -3.27M (-226.7%)
-17.95M
est: -4.37M (-310.8%)
-23.21M
est: -2.50M (-828.3%)
-21.59M
est: -3.69M (-485.5%)
-28.40M
est: -7.81M (-263.8%)
-36.57M
est: -3.18M (-1,048.8%)
-11.33M
-12.37M – -10.29M
-255.9% YoY
-2.89M
-3.16M – -2.63M
+74.5% YoY
-4.23M
-4.61M – -3.84M
-46.1% YoY
-79.61M
-86.89M – -72.33M
-1,783.6% YoY
-114.92M
-125.44M – -104.41M
-44.4% YoY
Net Income
-7.41M
est: -252.73M (+97.1%)
-9.69M
est: -143.40M (+93.2%)
-12.10M
est: -116.43M (+89.6%)
-8.98M
est: -62.47M (+85.6%)
-15.14M
est: -64.37M (+76.5%)
-23.21M
est: -23.23M (+0.1%)
-22.06M
est: -31.52M (+30.0%)
-25.97M
est: -28.09M (+7.5%)
-29.43M
est: -37.58M (+21.7%)
-4.34M
-27.05M – 36.07M
+88.4% YoY
-18.99M
-22.79M – -15.19M
-337.5% YoY
-6.25M
-7.00M – -5.51M
+67.1% YoY
57.11M
50.32M – 63.91M
+1,013.5% YoY
66.13M
58.27M – 74.00M
+15.8% YoY
SGA
1.91M
est: 1.18M (+62.1%)
3.84M
est: 1.21M (+216.7%)
3.11M
est: 2.05M (+51.7%)
3.48M
est: 2.57M (+35.5%)
4.67M
est: 3.44M (+35.8%)
130.6K
est: 1.97M (-93.4%)
97.4K
est: 4.25M (-97.7%)
8.75M
est: 8.99M (-2.6%)
7.73M
est: 3.67M (+110.8%)
13.05M
11.85M – 14.24M
+255.9% YoY
3.33M
3.03M – 3.64M
-74.5% YoY
4.87M
4.42M – 5.31M
+46.1% YoY
91.68M
83.29M – 100.06M
+1,783.6% YoY
132.35M
120.24M – 144.45M
+44.4% YoY
EPS
-1.09
est: -0.89 (-22.5%)
-1.34
est: -0.51 (-165.3%)
-0.65
est: -0.41 (-58.5%)
-0.15
est: -0.22 (+31.8%)
-0.19
est: -0.23 (+16.2%)
-0.29
est: -0.28 (-3.6%)
-0.17
est: -0.10 (-62.1%)
-0.09
est: -0.09 (-2.3%)
-0.10
est: -0.12 (+15.6%)
-0.03
-0.09 – 0.12
+70.7% YoY
-0.06
-0.08 – -0.05
-85.8% YoY
-0.02
-0.02 – -0.02
+67.1% YoY
0.19
0.17 – 0.21
+1,013.5% YoY
0.22
0.19 – 0.25
+15.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-28 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-27 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-26 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-25 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-22 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-21 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-20 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-19 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-18 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-15 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-14 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-13 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-12 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-11 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-08 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-07 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-06 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-05 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-05-04 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-04-30 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-04-29 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-04-28 C+ 2/5 3/5 1/5 1/5 3/5 1/5 3/5
2026-04-27 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-24 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-23 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-22 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-21 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-20 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-17 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5
2026-04-16 C 2/5 3/5 1/5 1/5 2/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-50.60M
OE per share TTM
-0.17
Owner's Yield
-41.93%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
49.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
306.00M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Amit D. Munshi Chairman & Interim CEO — male
Bernd Schmidt Chief Technical Officer — male
Christine Le Bec Head of CMC Gene Therapy — female
Geraldine Honnet Chief Medical Officer — —
Laurene Danon Chief Financial Officer — female
Laurent Desire Head of Preclinical Development — male
Rachel Cooper Head of Audiology — —
Stephanie Filipe Head of Business Operations & Portfolio Management — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology